| Document Date: 2014-05-08 09:31:02
Open Document File Size: 303,79 KBShare Result on Facebook
City Copenhagen / / Company Novartis / DuoBody / Kirin / ADCT / J&J / / Country United States / Sweden / Denmark / / Currency EUR / / / Event Business Partnership / FDA Phase / / IndustryTerm online dialogue / online network / online chat communication / financial media / investor meetings / online marketing / antibody enhancing technology / / Person JAN VAN DE WINKEL Q / Jan Van de Winkel Daratumumab / JAN VAN DE WINKEL / EGRF IND / David Eatwell / / / Position CEO / private investor / / Product rituxan / DuoBody Q&A GENMAB 8TH / EGFr / Q1 / / RadioStation 2014 WITH / / Technology ADC / antibody enhancing technology / Xencor technology / antibodies / HexaBody technology / Cytotoxic Fc Domain technology / / URL www.tcpdf.org / www.proinvestor.com/ir/en / /
SocialTag |
Q&A GENMAB 8TH OF MAY 2014 WITH JAN VAN DE WINKEL Q&A GENMAB 8TH OF MAY 2014